{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:47:43Z","timestamp":1778798863065,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005891","name":"State Administration of Traditional Chinese Medicine of The Peoples Republic of China","doi-asserted-by":"publisher","award":["ZYYCXTD-C-202005"],"award-info":[{"award-number":["ZYYCXTD-C-202005"]}],"id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10303502-002-019"],"award-info":[{"award-number":["2018ZX10303502-002-019"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10725506-002-001"],"award-info":[{"award-number":["2018ZX10725506-002-001"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013279","name":"National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["2017ZX09301022"],"award-info":[{"award-number":["2017ZX09301022"]}],"id":[{"id":"10.13039\/501100013279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clinre.2022.102009","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T01:28:29Z","timestamp":1660440509000},"page":"102009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The progression of chronicity and autoimmune hepatitis in recurrent drug-induced liver injury"],"prefix":"10.1016","volume":"46","author":[{"given":"Tingting","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohe","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6208-150X","authenticated-orcid":false,"given":"Zhaofang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2022.102009_bib0001","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.clinre.2022.102009_bib0002","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2022.102009_bib0003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/bmm.13.154","article-title":"Evaluation of database-derived pathway development for enabling biomarker discovery for hepatotoxicity","volume":"8","author":"Hebels","year":"2014","journal-title":"Biomark Med"},{"key":"10.1016\/j.clinre.2022.102009_bib0004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.humpath.2017.08.029","article-title":"Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center","volume":"68","author":"Ettel","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clinre.2022.102009_bib0005","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/hep.24022","article-title":"Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review","volume":"52","author":"Hunt","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2022.102009_bib0006","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following drug-induced liver injury","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2022.102009_bib0007","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jhep.2010.12.041","article-title":"Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis","volume":"55","author":"Lucena","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2022.102009_bib0008","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11901-018-0411-0","article-title":"Long-term outcomes after drug-induced liver injury","volume":"17","author":"Hayashi","year":"2018","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.clinre.2022.102009_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cld.2019.09.006","article-title":"Drug-Induced Liver Injury in the Setting of Chronic Liver Disease","volume":"24","author":"Hoppmann","year":"2020","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinre.2022.102009_bib0010","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","article-title":"Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury","volume":"65","author":"Medina-Caliz","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2022.102009_bib0011","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3390\/ijms18091954","article-title":"\"Autoimmune(-Like)\" drug and herb induced liver injury: new insights into molecular pathogenesis","volume":"18","author":"Sebode","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2022.102009_bib0012","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinre.2022.102009_bib0013","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2022.102009_bib0014","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2022.102009_bib0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2022.102009_bib0016","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1155\/2019\/9437043","article-title":"Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies","volume":"2019","author":"Sucher","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.clinre.2022.102009_bib0017","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/liv.12958","article-title":"Chronic liver injury induced by drugs: a systematic review","volume":"35","author":"Stine","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2022.102009_bib0018","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","article-title":"Drug-induced autoimmune-like hepatitis","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2022.102009_bib0019","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.3390\/ijms22094557","article-title":"Immune-mediated drug-induced liver injury: immunogenetics and experimental models","volume":"22","author":"Gerussi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2022.102009_bib0020","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3892\/mmr.2015.4659","article-title":"Heterophyllin B inhibits the adhesion and invasion of ECA-109 human esophageal carcinoma cells by targeting PI3K\/AKT\/\u03b2-catenin signaling","volume":"13","author":"Tantai","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.clinre.2022.102009_bib0021","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.intimp.2020.107352","article-title":"Psoralidin, a major component of Psoraleae Fructus, induces inflammasome activation and idiosyncratic liver injury","volume":"92","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clinre.2022.102009_bib0022","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.apsb.2020.03.006","article-title":"Icariside \u2161, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.clinre.2022.102009_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114796","article-title":"Isoxanthohumol, a component of Sophora flavescens, promotes the activation of the NLRP3 inflammasome and induces idiosyncratic hepatotoxicity","volume":"285","author":"Lin","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.clinre.2022.102009_bib0024","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12072-021-10144-3","article-title":"Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines","volume":"15","author":"Devarbhavi","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.clinre.2022.102009_bib0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0034-1375959","article-title":"Drug-induced liver injury with autoimmune features","volume":"34","author":"deLemos","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clinre.2022.102009_bib0026","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1081\/DMR-200028812","article-title":"Drug bioactivation, covalent binding to target proteins and toxicity relevance","volume":"37","author":"Zhou","year":"2005","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.clinre.2022.102009_bib0027","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/1389200023337333","article-title":"Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system","volume":"3","author":"Ju","year":"2002","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinre.2022.102009_bib0028","article-title":"Features and outcome of AIH patients without elevation of IgG","volume":"2","author":"Hartl","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clinre.2022.102009_bib0029","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep4.1687","article-title":"Multiparametric magnetic resonance imaging, autoimmune hepatitis, and prediction of disease activity","volume":"5","author":"Arndtz","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinre.2022.102009_bib0030","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep4.1889","article-title":"Noninvasive prediction of outcomes in autoimmune hepatitis-related cirrhosis","volume":"6","author":"Llovet","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinre.2022.102009_bib0031","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12072-021-10170-1","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis","volume":"15","author":"Wang","year":"2021","journal-title":"Hepatol Int"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:52Z","timestamp":1761895972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740122001437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2210740122001437"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102009","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The progression of chronicity and autoimmune hepatitis in recurrent drug-induced liver injury","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102009"}}